NCT03495427View on ClinicalTrials.gov

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 18, 2019

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2029

Conditions
Prostate CancerRecurrent Prostate Cancer
Interventions
DRUG

F-DCFPyL Injection

F-DCFPyL Injection is a radioactive diagnostic imaging agent indicated for imaging of patients with recurrent prostate cancer.

DIAGNOSTIC_TEST

PSMA PET

PSMA PET imaging (for men with high GC \>0.45) will be done after 2 years post-treatment, then yearly up to 5 years.

Trial Locations (1)

33612

RECRUITING

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
collaborator

Progenics Pharmaceuticals, Inc.

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER